Home 2023

Pfizer

Meeting on the Mesa: How to Bring Cell and Gene Therapies to Market
Bioprocessing

Meeting on the Mesa: How to Bring Cell and Gene Therapies to Market

Jonathan D Grinstein, PhD -
0
Biopharma Taps Bioprocessing 4.0, Benefits Start Flowing
Bioprocessing

Biopharma Taps Bioprocessing 4.0, Benefits Start Flowing

Kathy Vuksanaj -
0
Obesity, Alzheimer’s Drugs to Drive Sales as Patent Cliff Concerns Ebb
Drug Discovery

Obesity, Alzheimer’s Drugs to Drive Sales as Patent Cliff Concerns Ebb

Alex Philippidis -
0
Conscious Re-Coupling: M&A Comes Back Surely, If Slowly
Bioprocessing

Conscious Re-Coupling: M&A Comes Back Surely, If Slowly

Alex Philippidis -
0
Biomanufacturers Take a Two-Pronged Approach to Digitalization
Bioprocessing

Biomanufacturers Take a Two-Pronged Approach to Digitalization

Kathy Vuksanaj -
0
Top 10 U.S. Biopharma Clusters
A-Lists

Top 10 U.S. Biopharma Clusters

Alex Philippidis -
0
In Vivo Genome Editing of Stem Cells Induced by LNP-Based Delivery of mRNA
Cancer

In Vivo Genome Editing of Stem Cells Induced by LNP-Based Delivery of mRNA

Jonathan D Grinstein, PhD -
0
StockWatch: Caribou Shares Surge on $25M Pfizer Investment
GEN Edge

StockWatch: Caribou Shares Surge on $25M Pfizer Investment

Alex Philippidis -
0
Samsung Biologics Inks Extended Deals Worth $897 Million with Pfizer
Bioprocessing

Samsung Biologics Inks Extended Deals Worth $897 Million with Pfizer

John Sterling -
0
As Patent Cliff Looms for Biopharma Giants, Smaller Biotechs Face Cash Crunch
Bioprocessing

As Patent Cliff Looms for Biopharma Giants, Smaller Biotechs Face Cash Crunch

Alex Philippidis -
22
1234Page 1 of 4
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.